Nebenwirkungen · Comirnaty
Comirnaty LP.8.1 30 micrograms/dose dispersion for injection Comirnaty LP.8.1 30 micrograms/dose dispersion for injection in pre-filled syringe Comirnaty LP.8.1 10 micrograms/dose dispersion for injection COVID−19 mRNA Vaccine · Abschnitt 4.8 · PDF-Seite 115
HOS-149074 · Präparat HOS-099980
In a subset from Study 4 (Phase 3), 305 adults > 55 years of age who had completed 3 doses of Comirnaty, received a booster (fourth dose) of Comirnaty 5 to 12 months after receiving Dose 3. Participants who received a booster (fourth dose) of Comirnaty had a median follow-up time of at least 1.7 months up to a data cut-off date of 16 May 2022. The overall safety profile for the Comirnaty booster (fourth dose) was similar to that seen after the Comirnaty booster (third dose). The most frequent adverse reactions in participants > 55 years of age were injection site pain (> 60%), fatigue (> 40%), headache (> 20%), myalgia and chills (> 10%).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-06T16:00:00Z · SHA-256 6b1fcd6e0ff3b5c1ffd59f9dd3286f1609cca5902765a0cf59830512428fefdc · Passage 80ee242c31de85c6f4c48fe4228c02b93b238ada26636e7aa1a8e36976ddac8e · Zeichen 7962–8608 im Abschnitt